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Abstract 
There is considerable current interest in novel treatments for virally-associated pneumonia. Ten 
radiobiological animal datasets (generally dating from the 1920s to early 1970s) in which bacterial 
or viral agents were administered to induce pneumonia in animals that were also exposed to 
moderate doses of radiation before or after inoculation, are reanalyzed with state-of-the-art 
statistical models. A number of different model system and types of challenging infection are 
considered. The results are heterogeneous, with  some data showing an increase in risk associated 
with radiation exposure, whether before or after inoculation, and some showing a decrease in risk. 
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Introduction 
Over the last two decades, humans have encountered three substantial outbreaks of new 
coronavirus (CoV) epidemics. The first, in the early 2000s, was caused by Middle East respiratory 
syndrome (MERS)-CoV (1). The second, in the 2010s, was caused by the severe acute respiratory 
syndrome (SARS)-CoV (2). Lastly, the ongoing outbreak is caused by the SARS-CoV-2 (now 
termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO)(3)) 
emerged in China in December 2019, resulting in more than 90,000 deaths as of 9 April 2020 (4). 
The lungs represent one of the organs most affected by COVID-19, and some patients develop 
life-threatening viral pneumonia and sepsis. Currently there are few clinical management options 
available for COVID-19 patients with pneumonia, beyond the supply of oxygen and administration 
of antibiotics to avoid co-infection, and possibly, though not recommended, administration of 
corticosteroids (5). There is ongoing discussion of the potential use of diagnostic x-irradiation, 
most notably by computerized tomography (CT) scanning for COVID-19 related lung pathology 
(6-8). Clinical studies on several potential therapeutic agents are being conducted (9-11), such as 
favipiravir, lopinavir and remdesivir (9-11). 
In the early part of 20th century, a number of attempts were made to treat various non-cancer 
diseases with ionizing radiation, including virally- or bacterially-associated pneumonia. In 2013, 
Calabrese and Dhawan (12) reviewed 19 papers, mostly case reports, describing outcomes from 
low dose radiotherapy with X-rays (LDRT) for pneumonia, among them 3 papers published in 
1905–1916 and 16 published between 1925–1943. Their review identified a total of 863 cases, 
among which 717 showed good clinical response within three days of treatment (12). However, 
the human data reviewed were limited to case series, many based on small numbers of subjects. 
As the sampling framework in these case reports is unknown, they are subject to ascertainment 
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bias and are effectively uninterpretable. The doses used are also often unknown. Calabrese and 
Dhawan (12) also identified three radiobiological studies, all from experiments done in the 1940s, 
namely Fried (13) using a guinea pig model, Lieberman et al. (14) using a canine model and Dubin 
et al. (15) using a murine model, the first two of these for bacterially-induced pneumonia and the 
last for virally-induced pneumonia. For reasons that are not clear there are at least eight relevant 
radiobiological studies that were not considered in the review of Calabrese and Dhawan (12). 
Calabrese and Dhawan (12) did not attempt any statistical reanalysis of this old data. The aim of 
the present paper is to look at more nearly the totality of radiobiological data relating to radiation 
exposure before or after inoculation with a viral or bacterial agent likely to result in pneumonia. 
Because of the age of the data being considered there are shortcomings in the original statistical 
analysis that was performed – indeed in all but a few cases (16,17) there does not appear to have 
been any formal statistical analysis in the original reports. It is the purpose of this paper to report 
reanalysis of this data so far as that is achievable, using state-of-the-art statistical survival models 
in order to assess modification of pneumonia morbidity or mortality risk by radiation exposure 
before or after inoculation..  
 
Methods 
The datasets used are listed in Table 1. We convert the given free-in-air dose in rad or rep in all 
studies to Gy via the scaling 1 rad/rep =0.00877 Gy (18).  
 
Statistical methods 
Mortality risks in the radiobiological cohorts of Murphy and Sturm (19), Lieberman et al. (14), 
Dubin et al. (15)  and Quilligan et al. (20) were assessed using a Cox proportional hazards models 
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(21), with time after radiation exposure, if that followed the inoculation, or time after bacterial or 
viral inoculation, if that followed the radiation exposure,  as timescale, in which the relative risk 
(RR) (=hazard ratio) of death for animal i  at time a  after inoculation was given by a linear model 
in dose: 
[ , | ] [1 ]i i iRR a D Dα α= +         (1) 
or alternatively using a log-linear model in dose: 
[ , | ] exp[ ]i i iRR a D Dα α=         (2) 
where iD  is the total dose (in Gy), α  is the excess relative risk coefficient (ERR) per unit dose 
(Gy). For the dataset of Murphy and Sturm (19) the only usable information available is the fact 
of irradiation of the mice (yes or no), so that the model fitted is of the form: 
exposure exposure[ ,1 | ] exp[ 1 ]i ii yesRR a α α ==       (3) 
For the most other datasets a linear logistic model is fitted to the data (generally on number of 
animals died in each group): 
0 1 0 1 0 1[ , | , ] exp[ ][1 ] / [1 exp[ ][1 ]]i i i iP a D D Dα α α α α α= + + +    (4) 
Occasionally the more standard log-logistic model is fitted to the data (generally on number of 
animals died in each group): 
0 1 0 1 0 1[ , | , ] exp[ ] / [1 exp[ ]]i i i iP a D D Dα α α α α α= + + +    (5) 
The models were fitted via Epicure (22). All confidence intervals and two-sided p-values are 
profile-partial-likelihood based (23). In the murine dataset of Dubin et al. (15) in various 
subgroups risks were assessed in relation to radiation dose administered after inoculation or dose 
before inoculation. In the murine dataset of Quilligan et al (20) both pre-inoculation and post-
inoculation dose was given to all animals, and both were employed in the  model, although 
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problems of convergence arose, so that the univariate analyses were more reliable and to be 
preferred. The model was stratified by the three experiments reported in the data of Dubin et al. 
(15) and by the three groups used by Lieberman et al. (14). Tables 1 and 2 and Figure 1 and 2 
show the risks in relation to dose for these two datasets. In the analysis of the data from Hale and 
Stoner (24) in some cases adjustment was made for the type of challenging infection. In the fits to 
the pneumonia intensity data of Baylin et al. (25) we used either log-logistic regression (as 
described above) comparing each intensity group and those with greater intensity vs every group 
with reduced intensity; we also used ordinal regression with log-linear link (26) fitting to all the 
ordered intensity groups. In fits of the days of infection data of Baylin et al. (25) we used a linear 
regression model. In order to estimate confidence intervals we employed the bias-corrected 
advanced intervals (27).  The data of Fried (28), with only 6 guinea pigs, 3 irradiated and 3 
unirradiated after inoculation with Staphylococcus aureus, was too small to fit a stable model.  
 
Results 
Radiation administration after inoculation 
Table 2 demonstrates that there is a highly significant decreasing trend (p<0.001) of mortality with 
post-inoculation dose in the dataset of Lieberman et al. (14) with EOR per Gy = -0.23 (95% CI -
0.24, -0.16), as also shown by Figure 1. However, Table 2 shows that this is largely driven by a 
single group, group 3, as also shown by Figure 2. There is no significant trend with dose (p>0.5) 
in the murine data of Tanner and McConchie (29) (Table 3). 
There few indications of trend of degree of pneumonia infection with dose in the feline data 
of Baylin et al. (25), whether using logistic or ordinal models (Table 4). Only for logistic regression 
of slight to moderate pneumonia intensity vs everything below is there a borderline indication of 
Version of 6th August 2020 
7 
 
an increasing trend with ln[OR] /Gy = 1.32 (95% CI -0.16, 3.17) (p=0.082) i.e. intensity of 
infection increasing with dose. However, Table 5 indicates that there is a significant decreasing 
trend of days of acute infection with dose in this dataset, with days of infection / Gy changing by 
-2.51 (95% CI -5.05, -0.09) (p=0.026), i.e., duration of infection decreasing with dose, as also 
shown by Figure 3. Table 6 demonstrates that there is a highly significant (p<0.001) increased risk 
of death associated with X-ray exposure after inoculation with pneumococcus in the murine data 
of Murphy and Sturm (19), with RR = 3.67 (95% CI 1.84, 7.61).   
 
Radiation administration before and after inoculation 
Table 7 demonstrates that there is no significant trend (p>0.4) with post-inoculation dose in the 
data of Dubin et al. (15), whether using linear or log-linear models, which is confirmed also by 
Figure 1. However, there is a borderline significant decreasing trend (p=0.03) of mortality with 
pre-inoculation dose in this dataset, with EOR/Gy = -0.62 (95% CI -0.90, -0.09) again confirmed 
by Figure 1. Table 8 indicates that there is a highly significant (p<0.001) decrease in risk in the 
C57BL mouse data of Quilligan et al (20) associated with post-influenza-inoculation radiation 
dose with ERR/Gy = -0.07 (95% CI -0.08, -0.07). Table 8 suggests that by contrast there is no 
trend with pre-inoculation dose (p>0.5) in this data with ERR/Gy = 0.03 (95% CI <-100, >100) 
(20); analysis in which both pre-inoculation and pre-inoculation dose were incorporated yielded 
indications of non-convergence, although the directions of effect were consistent with those of the 
univariate analyses (Table 8).   
 
Radiation administration before inoculation 
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Table 9 shows that there is generally highly significant (p<0.005) increase in risk associated with 
radiation before inoculation with influenza virus, pneumococcus type III bacterial infection or 
trichinella spiralis larval infection in Swiss mice data of Hale and Stoner (24), whether adjusted 
or not for type of first immunizing infection, so that for example with such adjustment and 
excluding the trichinella spiralis challenge infections the EOR/Gy = 1.71 (95% CI 0.97, 3.02). 
Pneumonitis morbidity and mortality were significantly decreased (p<0.001) after 3.5 Gy whole 
body air dose exposure in adult male albino CF-1 mice in the data of Berlin (16), so that for 
pneumonitis morbidity the EOR/Gy = -0.24 (95% CI -0.28, -0.17) and for pneumonitis mortality 
the EOR/Gy = -0.21 (95% CI -0.26, -0.14), as shown in Table 10. In contrast Table 11 shows 
reanalysis of slightly later data of Berlin and Cochran (17), which exhibits slightly heterogeneous 
results, with one set of experiments (given in Table III of Berlin and Cochran (17)) indicating a 
significant increase (p<0.05) in influenza mortality, whether or not adjusted for mode of 
administration of virus, but a different experimental set  (reported in Table II of the paper) showing 
no significant effect  (p>0.1) of radiation exposure on influenza morbidity or mortality. These 
experiments use a similar murine system, also given 3.5 Gy whole body air-dose exposure, as in 
the earlier paper of Berlin (16). Lundgren et al (30) used a novel type of radiation exposure, 
aerosolized 144CeO2, which delivers localized β dose to the lungs of C57BL/6J mice. As can be 
seen from Table 12 there was a small but highly significant increase in mortality risk associated 
with radiation exposure, with EOR/Gy = 0.008 (95% CI 0.002, 0.019, p=0.002).  
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Table 1. Data used for re-analysis 
Author Ref. Animal strain Infective agent(s) Endpoint(s) analyzed Range of 
dose (Gy) 
No of 
animals 
Statistical model used 
for re-analysis 
Murphy and Sturm (19) White mice Type I pneumococcus Mortality NA 75 Linear Cox 
Lieberman et al. (14) Dogs Type I+III pneumococcus Mortality 0.0-4.096 45 Linear Cox 
Dubin et al. (15) White mice Swine influenza virus Mortality 0.0-1.754 252 Linear Cox 
Baylin et al. (25) Cats Feline virus (Baker) Degrees of pneumonia 0.0-1.754 24 Log logistic + ordinal 
Tanner and McConchie (29) CFW mice Theilers FA mouse encephalitis virus Mortality 0.0-1.754 196 Linear logistic 
Hale and Stoner  (24) Swiss mice Influenza type A, trichinella spiralis, 
pneumococcus type III 
Mortality 0.0-6.139 658 Linear logistic 
Quilligan et al. (20) C57BL male mice PR8 strain type A influenza virus Mortality 1.263-24.65 32,970 Linear Cox 
Berlin (16) CF-1 adult albino 
male mice 
CAM A-prime strain influenza virus Morbidity+mortality 0.0-3.070 362 Linear logistic 
Berlin and Cochran (17) CF-1 adult albino 
male mice 
PR8 strain type A influenza virus Morbidity+mortality 0.0-4.385 660 Linear logistic 
Lundgren et al. (30) Female C57BL/6J 
mice 
Type A0 influenza virus Mortality 0.0-166.63 364 Linear logistic 
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Table 2. Risks of death associated with radiation exposure in the canine data of Lieberman et al. (14) by study group 
Model Group 
ERR / Gy (+95% 
CI) p-value 
Linear Group 1 -0.05 (-0.35, 0.86) 0.860 
Loglinear Group 1 -0.05 (-0.58, 0.50) 0.861 
Linear Group 2 -0.37 (-0.41, 0.82) 0.157 
Loglinear Group 2 -1.75 (-6.25, 0.27) 0.096 
Linear Group 3 -0.23 (-0.24, -0.16) <0.001 
Loglinear Group 3 -0.68 (-1.11, -0.29) <0.001 
Linear All groups -0.23 (-0.24, -0.16) <0.001 
Loglinear All groups -0.49 (-0.81, -0.19) <0.001 
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Table 3. Risks of death in mice associated with radiation exposure post inoculation to FA 
strain mouse encephalitis virus in the data of Tanner and McConchie (29), via fit of linear 
logistic model 
EOR / Gy + 95% CI p-value 
-0.19 (-0.51, 0.90) 0.580 
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Table 4. Logistic regression of intensity of pneumonia infection  vs dose in feline data of 
Baylin et al (25) 
Group ln[OR] / Gy + 95% CI p-value 
Logistic regression 
Very slight and above vs none 21.51 (<-100, >100) 0.173 
Slight and above vs everything below 1.36 (-0.88, 4.84) 0.256 
Slight to moderate and above vs everything below 1.32 (-0.16, 3.17) 0.082 
Moderate and above vs everything below 0.56 (-0.89, 2.13) 0.446 
Moderate to marked and above to everything below -1.36 (-4.84, 0.88) 0.256 
Marked vs everything below 0.66 (-3.06, 4.45) 0.690 
Ordinal regression 
 0.73 (-0.51, 2.03) 0.246 
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Table 5. Linear regression of days of acute pneumonia infection  vs dose in data of Baylin et 
al (25) 
days / Gy + 95% bootstrap CI BCA Bootstrap p-value 
-2.51 (-5.05, -0.09) 0.026 
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Table 6. Relative risk of mortality in mice given X-rays after inoculation with type I 
pneumococcus of Murphy and Sturm (19) via fit of a Cox proportional hazards model 
 
Relative risk 
(hazard ratio) (+ 
95% CI) p-value 
X-ray vs not 3.67 (1.84, 7.61) <0.001 
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Table 7. Risks of death associated with radiation exposure in white mice data of Dubin et al. 
(15), evaluated using a Cox proportional hazards model  
Dose post-inoculation 
Model ERR / Gy (+95% CI) p-value 
Linear -0.13 (-0.35, 0.27) 0.451 
Loglinear -0.14 (-0.51, 0.23) 0.454 
Dose pre-inoculation 
Model ERR / Gy (+95% CI) p-value 
Linear -0.62 (-0.90, -0.09) 0.029 
Loglinear -0.92 (-1.84, -0.10) 0.028 
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Table 8. Risks of death in male C57BL mice associated with 60Co radiation exposure pre- 
and post-inoculation to intranasally administered PR8 strain of type A influenza virus in the 
data of Quilligan et al (20), via fit of a Cox proportional hazards model 
 ERR / Gy + 95% CI p-value 
Pre-inoculation dose unadjusted for post-inoculation dose -0.07 (-0.08a, -0.07) <0.001 
Post-inoculation dose unadjusted for pre-inoculation dose 0.03 (<-100 a, >100 a) 1.000 
Pre-inoculation dose adjusted for post-inoculation dose -3.40b (-4.73a, -2.06a) <0.001b c 
Post-inoculation dose adjusted for pre-inoculation dose 2.83b (1.66 a, 4.00a) <0.001b d 
aWald based CI. 
bindications of non-convergence. 
cp-value of improvement in fit of model with pre- and post-inoculation dose in comparison with model with only post-inoculation 
dose. 
dp-value of improvement in fit of model with pre- and post-inoculation dose in comparison with model with only pre-inoculation 
dose. 
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Table 9. Risks of death in Swiss mice associated with radiation exposure pre-inoculation to 
mixture of influenza virus, pneumococcus type III bacterial infection and larval infection by 
trichinella spiralis in the data of Hale and Stoner (24), via fit of a linear logistic model 
 EOR / Gy + 95% CI p-value 
Unadjusted, all data 0.11 (0.03, 0.21) 0.004 
Unadjusted, fitted to experiments with influenza and pneumococcus 
challenge infections only 0.27 (0.13, 0.48) <0.001 
Adjusted for type of challenge infection typea 1.91 (1.12, 3.33) <0.001 
Adjusted for challenge infection type, fitted to experiments with influenza 
and pneumococcus challenge infections onlya 1.71 (0.97, 3.02) <0.001 
ainfluenza virus, pneumococcus type III bacterial infection, larval infection by trichinella spiralis
Version of 6th August 2020 
18 
 
Table 10. Morbidity and mortality risks associated with pre-inoculation radiation exposure 
in CF-1 adult albino male data of Berlin (16) via fit of a linear logistic model 
 
EOR / Gy + 95% 
CI p-value 
Pneumonitis morbidity -0.24 (-0.28, -0.17) <0.001 
Pneumonitis mortality -0.21 (-0.26, -0.14) <0.001 
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Table 11. PR8 Type A influenza morbidity and mortality risks associated with pre-
inoculation radiation exposure in CF-1 adult albino male data of Berlin and Cochran (17), 
evaluated using a linear logistic model 
 EOR / Gy + 95% CI p-value 
Table II data – analysis of influenza mortality and morbidity 
Influenza morbidity -0.11 (-0.18, 0.05) 0.132 
Influenza mortality -0.04 (-0.15, 0.26) 0.711 
Table III data – analysis of influenza mortality considering mode of administration of virus 
Unadjusted for mode of administration of influenza virus 0.21 (0.03, 0.48) 0.020 
Adjusted for mode of administration of influenza virus 0.25 (0.05, 0.57) 0.009 
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Table 12.   Mortality risks associated with pre-inoculation 144CeO2 radiation exposure in 
C57BL/6J mouse data of Lundgren et al (30), evaluated using a linear logistic model 
 EOR / Gy + 95% CI p-value 
Mortality 0.008 (0.002, 0.019) 0.002 
 
Version of 6th August 2020 
21 
 
Figure 1. Dose response for mortality in the murine data of Dubin et al. (15) and in the canine 
data of Lieberman et al. (14) 
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Figure 2. Dose response for mortality in the canine data of Lieberman et al. (14), by study 
group. 
Group 1 
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Figure 3. Days of acute pneumonia infection  vs dose in data of Baylin et al (25) 
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Figure 4. Mortality in mice (+95% CI) after mouse encephalitis virus and post-inoculation 
radiation exposure in data of Tanner and McConchie (29) 
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